MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Replicate will receive research funding and could potentially receive up to approximately US$550 million
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
CSPC will receive an upfront payment of $100 million from AstraZeneca
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
India has taken the lead in recognising NAFLD as a major non-communicable disease
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
